Results 41 to 50 of about 55,654 (235)

Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study [PDF]

open access: yes, 2021
Shereen A Sayed,1 Ehsan AB Hassan,2 Muhamad R Abdel Hameed,3 Michael N Agban,2 Mostafa F Mohammed Saleh,3 Hayam H Mohammed,4 Abu-Baker M Abdel-Aal,5 Sherein G Elgendy2 1Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Assiut ...
Abdel-Aal ABM   +7 more
core  

Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates

open access: yesBrazilian Journal of Infectious Diseases, 2016
The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and ...
Thaís Felli Kubiça   +6 more
doaj   +1 more source

Fluconazole resistance in non-albicans Candida species in the United States, 2012-2021

open access: yesAntimicrobial Stewardship & Healthcare Epidemiology, 2023
Background: Candida spp can cause a variety of infections known as candidiasis, ranging from severe invasive infections to superficial mucosal infections of the mouth and vagina.
Emily Jenkins   +6 more
doaj   +1 more source

A narrow bandgap Schottky heterojunction Fe2N/CeO2 microneedle triggering sonodynamic reactive oxygen species storm for drug‐resistance‐free skin fungal infection

open access: yesBMEMat, EarlyView.
Inorganic sonosensitizers suffer from inefficient electron‐hole separation, rapid recombination, and wide bandgaps in anti‐fungal applications. We propose MN@Fe2N/CeO2 to directly eliminate fungi without drug resistance. Combining semiconductor CeO2's advantages with Fe2N's high work function and activity enables efficient Schottky heterojunctions ...
Li Wang   +13 more
wiley   +1 more source

Effectiveness of voriconazole therapy for pulmonary cryptococcosis in fluconazole treatment failure: a multicenter real-world study

open access: yesBMC Infectious Diseases
Introduction Current guidelines recommend fluconazole as first-line therapy for pulmonary cryptococcosis. However, clinical reports indicate that fluconazole treatment fails in some patients.
Dian Yuan   +6 more
doaj   +1 more source

Redefining pleiotropic drug resistance in a pathogenic yeast: Pdr1 functions as a sensor of cellular stresses in Candida glabrata

open access: yesmSphere, 2023
Candida glabrata is a prominent opportunistic fungal pathogen of humans. The increasing incidence of C. glabrata infections is attributed to both innate and acquired resistance to antifungals.
Andrew N. Gale   +5 more
doaj   +1 more source

Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden

open access: yesChemFoodChem, EarlyView.
ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley   +1 more source

Interchangeability of Fluconazole Drugs [PDF]

open access: yes, 2018
Fluconazole – an antifungal agent belonging to the chemical class of triazole derivatives – is represented in the Russian pharmaceutical market by a large number of generic drugs. An important issue of rational pharmacotherapy is the demonstration of the
N. D. Bunyatyan   +3 more
core   +2 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet   +11 more
wiley   +1 more source

Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections

open access: yeseLife, 2020
Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited treatments.
Morgan A Wambaugh   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy